Axelyf

Adalid Science

Adalid Sciences develops lipid nanoparticle delivery systems for nucleic acid therapeutics, serving pharmaceutical companies, biotechnology start-ups, and contract development and manufacturing organisations.

Ayuvant

The company develops RNA nanoparticle immunotherapies to treat cancer patients who do not respond to existing immune checkpoint inhibitors.

Capstan Therapeutics

Capstan Therapeutics develops in vivo RNA-based therapies for patients with autoimmune diseases and cancers using targeted lipid nanoparticle technology.

Hone Bio

This company develops lipid nanoparticle targeting technology for pharmaceutical and biotechnology firms to enable precise drug delivery beyond the liver.

ExcepGen

ExcepGen develops a platform for nucleic acid therapeutics to improve the efficacy and tolerability of mRNA-based medicines for biopharmaceutical companies.

Akribion Therapeutics

The company develops RNA-guided nuclease technology for programmable cell depletion to treat cancer and autoimmune diseases for healthcare providers and patients.

CamGene

This company develops RNA-based therapeutics using lipid nanoparticle technology to treat hearing loss for patients with cellular dysfunction or undergoing cochlear implant surgery.

DTX Pharma

This biotechnology firm develops RNA-based therapeutics for patients with rare neuromuscular and central nervous system disorders using a proprietary fatty acid delivery platform.